Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care (SoC) Clear all
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, RDV Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)

NCT00803634
View directory record Official record
Conditions
Hypertension, Heart Failure
Interventions
Clevidipine, Standard of Care IV antihypertensive
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2014 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Study Assessing Complete Wound Healing by Comparing Surgenex® PelloGraft in Treating DFU and SanoGraft® in Treating VLU to SOC

NCT06515093
View directory record Official record
Conditions
Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions
PelloGraft, SanoGraft
Other
Lead sponsor
Surgenex
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Vista, California • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Healing Hearts of Hospitalized Patients

NCT06935604
View directory record Official record
Conditions
Well-Being, Psychological, Anxiety, Affect, Relaxation
Interventions
VR mindfulness application, Standard of Care (SOC)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 99 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

NCT06638944
View directory record Official record
Conditions
Dysphagia, Stroke, Parkinson Disease
Interventions
In-person sEMG-biofeedback, Remote sEMG-biofeedback, Standard-of-care treatment
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Champaign, Illinois • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Phase 2 Interventional

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

NCT07225621
View directory record Official record
Conditions
Glioblastoma, GBM
Interventions
5-ALA HCl + LIDU SDT, Placebo + Sham SDT
Combination Product
Lead sponsor
Alpheus Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional

Study of HST5040 in Subjects With Propionic or Methylmalonic Acidemia

NCT04732429
View directory record Official record
Conditions
Methylmalonic Acidemia, Propionic Acidemia
Interventions
HST5040, Placebo
Drug
Lead sponsor
HemoShear Therapeutics
Industry
Eligibility
2 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
14
States / cities
San Diego, California • New Haven, Connecticut • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Powered Exoskeletons in Persons With SCI

NCT02658656
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
ReWalk 6.0
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Long Beach, California • Palo Alto, California • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Retrospective Independent Safety Review of Closed Irrisept Study

NCT05359666
View directory record Official record
Conditions
Adverse Events
Interventions
Irrisept, Standard of Care
Device
Lead sponsor
Irrimax Corporation
Industry
Eligibility
Not listed
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers

NCT06550596
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Foot Ulcer, Diabetic Foot Ulcer
Interventions
Standard of Care, Axolotl DualGraft + SOC
Other
Lead sponsor
Axolotl Biologix
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Phase 4 Interventional

Multi-Center PAMPA Study

NCT05004727
View directory record Official record
Conditions
Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 1 Interventional

Phase I EGFR BATs in Newly Diagnosed Glioblastoma

NCT03344250
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme
Interventions
EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

CAMPR-II RWE TRIAL: A Saline-hydrated Allogeneic Dual-layer Amniotic Membrane Product or a Synthetic, Resorbable Polymeric Wound Matrix to a Coarsened Exact Matched Retrospective Control Cohort of Hard to Heal DFUs and VLUs

NCT07701590
View directory record Official record
Conditions
Wound, Foot, Diabetic Foot Ulcer (DFU), Venus Leg Ulcer
Interventions
Microlyte®, IP 1: Membrane Wrap - Hydro
Device
Lead sponsor
Capsicure, LLC
Network
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
7
States / cities
San Diego, California • Coral Gables, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Effectiveness of Central Oncology Navigation and the Use of an ORN

NCT06618274
View directory record Official record
Conditions
Cancer, Malignant Tumor
Interventions
Intervention of oncology research navigator embedded in central oncology navigation, Central oncology navigation (SOC)
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Terminated Not applicable Interventional Results available

The Computed Tomography-derived Fractional Flow Reserve STAT Trial

NCT03263806
View directory record Official record
Conditions
Heart Disease, Coronary, Chest Pain, Acute Coronary Syndrome
Interventions
CTFFR-Guided Group Management, SOC Group Management
Diagnostic Test
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 13, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT04553406
View directory record Official record
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Interventions
SPR720, Placebo, Open-label Standard of Care
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 13, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

NCT05631093
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ART, DOR/ISL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

NCT05009732
View directory record Official record
Conditions
Covid19
Interventions
GT0918, Standard of care, Matching placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Hialeah, Florida • Lansing, Michigan • Hannibal, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 13, 2026, 5:49 PM EDT
Active, not recruiting Phase 1 Interventional

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT05489237
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Interventions
IDRX-42
Drug
Lead sponsor
IDRX, Inc., a wholly owned subsidiary of GSK, LLC
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients

NCT02921789
View directory record Official record
Conditions
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Interventions
Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF), Tacrolimus Capsules, Methylprednisone, Prednisone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01644643
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 13, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Shockwave, Photobiomodulation, and Physical Therapy for Achilles Tendinopathy

NCT05751785
View directory record Official record
Conditions
Achilles Tendinopathy
Interventions
Physical Therapy, Shockwave Therapy, Photobiomodulation Therapy
Other · Device
Lead sponsor
Musculoskeletal Injury Rehabilitation Research for Operational Readiness
Federal
Eligibility
18 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 13, 2026, 5:49 PM EDT
Recruiting Not applicable Interventional

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

NCT06870812
View directory record Official record
Conditions
Stroke Hemorrhagic
Interventions
Surgical management, Medical Management
Procedure · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 13, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • Duarte, California • Glendale, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 13, 2026, 5:49 PM EDT